Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by PepGen Inc.
PepGen Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
August 08, 2024
From
PepGen Inc.
Via
Business Wire
Tickers
PEPG
PepGen Announces Positive Data from Low-Dose Cohort of PGN-EDO51 in Ongoing CONNECT1-EDO51 Phase 2 Clinical Trial for Treatment of Duchenne Muscular Dystrophy
July 30, 2024
From
PepGen Inc.
Via
Business Wire
Tickers
PEPG
PepGen Appoints Afsaneh Mohebbi, Ph.D., as SVP, Portfolio and Program Management and Dave Borah, CFA, as SVP, Investor Relations and Corporate Communications
July 02, 2024
From
PepGen Inc.
Via
Business Wire
Tickers
PEPG
PepGen Announces Executive Team Promotions
June 11, 2024
From
PepGen Inc.
Via
Business Wire
Tickers
PEPG
PepGen Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
May 14, 2024
From
PepGen Inc.
Via
GlobeNewswire
Tickers
PEPG
PepGen to Participate in Upcoming Investor Conferences
March 13, 2024
From
PepGen Inc.
Via
GlobeNewswire
Tickers
PEPG
PepGen Receives U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy
March 13, 2024
From
PepGen Inc.
Via
GlobeNewswire
Tickers
PEPG
PepGen Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments
March 06, 2024
From
PepGen Inc.
Via
GlobeNewswire
Tickers
PEPG
PepGen Announces Clearance of CTA by UK Medicines & Healthcare Products Regulatory Agency to Begin CONNECT2-EDO51, a Phase 2 Clinical Trial designed to support potential accelerated approval of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy
March 04, 2024
From
PepGen Inc.
Via
GlobeNewswire
Tickers
PEPG
PepGen Receives U.S. FDA Fast Track Designation for PGN-EDODM1 for the Treatment of Myotonic Dystrophy Type 1
February 20, 2024
From
PepGen Inc.
Via
GlobeNewswire
Tickers
PEPG
PepGen Announces Pricing of $80.1 Million Underwritten Offering of Common Stock
February 07, 2024
From
PepGen Inc.
Via
GlobeNewswire
Tickers
PEPG
Mary Beth DeLena Joins PepGen as General Counsel and Secretary
January 17, 2024
From
PepGen Inc.
Via
GlobeNewswire
Tickers
PEPG
PepGen Announces First Patient Dosed in CONNECT1-EDO51 Phase 2 Clinical Trial of PGN-EDO51 for Duchenne Muscular Dystrophy Patients Amenable to Exon 51 Skipping
January 08, 2024
From
PepGen Inc.
Via
GlobeNewswire
Tickers
PEPG
PepGen Announces First Patient Dosed in Phase 1 FREEDOM-DM1 Clinical Trial of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)
December 18, 2023
From
PepGen Inc.
Via
GlobeNewswire
Tickers
PEPG
PepGen Announces Appointment of Howard Mayer, M.D. to Board of Directors
November 15, 2023
From
PepGen Inc.
Via
GlobeNewswire
Tickers
PEPG
PepGen Reports Third Quarter 2023 Financial Results and Recent Corporate Developments
November 08, 2023
From
PepGen Inc.
Via
GlobeNewswire
Tickers
PEPG
PepGen Inc. Announces FDA has Lifted the Clinical Hold on its Investigational New Drug Application for FREEDOM-DM1 Phase 1 Study of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)
October 12, 2023
From
PepGen Inc.
Via
GlobeNewswire
Tickers
PEPG
PepGen Announces Upcoming Presentations at the 28th Annual Congress of the World Muscle Society and the World Congress of Neurology
September 27, 2023
From
PepGen Inc.
Via
GlobeNewswire
Tickers
PEPG
PepGen Inc. Announces Clearance of CTA by Health Canada to Begin the FREEDOM-DM1 Phase 1 Study of PGN-EDODM1 in Patients with Myotonic Dystrophy Type 1
September 06, 2023
From
PepGen Inc.
Via
GlobeNewswire
Tickers
PEPG
PepGen Inc. Presents PGN-EDODM1 Preclinical Data Supporting the Company’s Enhanced Delivery Oligonucleotide Platform and PGN-EDODM1 Program at Two Medical Conferences
September 06, 2023
From
PepGen Inc.
Via
GlobeNewswire
Tickers
PEPG
PepGen Announces Presentations at the 2023 Myotonic Dystrophy Foundation Annual Conference, Ottawa Neuromuscular Disease Meeting, and H.C. Wainwright 25th Annual Global Investment Conference
September 01, 2023
From
PepGen Inc.
Via
GlobeNewswire
Tickers
PEPG
PepGen Reports Second Quarter 2023 Financial Results and Recent Corporate Developments
August 08, 2023
From
PepGen Inc.
Via
GlobeNewswire
Tickers
PEPG
PepGen Inc. Provides Update on Planned Initiation of Phase 1 Study of PGN-EDODM1 in Myotonic Dystrophy Type 1
June 13, 2023
From
PepGen Inc.
Via
GlobeNewswire
Tickers
PEPG
PepGen Inc. Announces Clinical Hold in the U.S. on IND Application to Initiate a Phase 1 Study of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)
May 30, 2023
From
PepGen Inc.
Via
GlobeNewswire
Tickers
PEPG
PepGen Announces Clearance by Health Canada of CTA for PGN-EDO51 to Begin the Phase 2 Clinical Trial, CONNECT1-EDO51, for the Treatment of Duchenne Muscular Dystrophy
May 18, 2023
From
PepGen Inc.
Via
GlobeNewswire
Tickers
PEPG
PepGen Reports First Quarter 2023 Financial Results and Recent Corporate Developments
May 11, 2023
From
PepGen Inc.
Via
GlobeNewswire
Tickers
PEPG
PepGen to Host Fourth Quarter and Full Year 2022 Financial Results Call
March 16, 2023
From
PepGen Inc.
Via
GlobeNewswire
Tickers
PEPG
PepGen Announces Upcoming Data Presentations at the 2023 Annual Muscle Dystrophy Association Clinical and Scientific Conference
March 13, 2023
From
PepGen Inc.
Via
GlobeNewswire
Tickers
PEPG
PepGen to Participate in the SVB Securities Global Biopharma Conference
February 09, 2023
From
PepGen Inc.
Via
GlobeNewswire
Tickers
PEPG
PepGen Announces IND-Enabling Preclinical Data Supporting Progression of PGN-EDODM1 into Clinical Studies
December 07, 2022
From
PepGen Inc.
Via
GlobeNewswire
Tickers
PEPG
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.